DJO, a subsidiary of Colfax Corporation, announced the completion of its acquisition of MedShape, a privately-held orthopedic company focused on the foot and ankle market. Terms for the transaction were not disclosed.
MedShape’s portfolio addresses fracture fixation, joint fusion and soft injury repair with biomaterial technologies to improve patient outcomes. The company’s patented superelastic nickel titanium (NiTiNOL) shape memory alloy responds to changes at the surgical site to maintain compression and bony apposition throughout healing.
The move is another step in DJO’s strategic entry into the estimated $1 billion foot and ankle market that spurred the company’s 2020 acquisitions of Stryker’s STAR® product line and Trilliant Surgical®. The foot and ankle market tends to be fragmented, with a wide array of companies in the $20 million to $30 million revenue range, making them attractive acquisition targets for larger players. DJO leadership expects the business line to generate over $100 million in annual revenue within a few years.
DJO, a subsidiary of Colfax Corporation, announced the completion of its acquisition of MedShape, a privately-held orthopedic company focused on the foot and ankle market. Terms for the transaction were not disclosed.
MedShape's portfolio addresses fracture fixation, joint fusion and soft injury repair with biomaterial technologies to...
DJO, a subsidiary of Colfax Corporation, announced the completion of its acquisition of MedShape, a privately-held orthopedic company focused on the foot and ankle market. Terms for the transaction were not disclosed.
MedShape’s portfolio addresses fracture fixation, joint fusion and soft injury repair with biomaterial technologies to improve patient outcomes. The company’s patented superelastic nickel titanium (NiTiNOL) shape memory alloy responds to changes at the surgical site to maintain compression and bony apposition throughout healing.
The move is another step in DJO’s strategic entry into the estimated $1 billion foot and ankle market that spurred the company’s 2020 acquisitions of Stryker’s STAR® product line and Trilliant Surgical®. The foot and ankle market tends to be fragmented, with a wide array of companies in the $20 million to $30 million revenue range, making them attractive acquisition targets for larger players. DJO leadership expects the business line to generate over $100 million in annual revenue within a few years.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
